Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H17F3N4O3S |
| Molecular Weight | 474.456 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1[C@H](C2=C(C=C(C=C2)C#N)S(C)(=O)=O)C(C#N)=C(C)N(C1=O)C3=CC(=CC=C3)C(F)(F)F
InChI
InChIKey=YAJWYFPMASPAMM-HXUWFJFHSA-N
InChI=1S/C22H17F3N4O3S/c1-13-18(12-27)20(17-8-7-14(11-26)9-19(17)33(3,31)32)28(2)21(30)29(13)16-6-4-5-15(10-16)22(23,24)25/h4-10,20H,1-3H3/t20-/m1/s1
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Code | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
BAY-85-8501
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY | Official Title: A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY85-8501 in Patients With Non-Cystic Fibrosis BronchiectasisPurpose: The primary objective of this study is to assess the safety and tolerability of 28 day oral administration of BAY85-8501 versus placebo in subjects with non-CF Bronchiectasis (BE).The secondary objectives are to examine the effect of BAY85-8501 on pulmonary function, biomarkers of inflammation and tissue damage, and the impact on overall health and perceived well-being and to evaluate the pharmacokinetics of BAY85-8501. | ||
|
BAY-85-8501
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY | Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). | ||
|
66601502
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY | |||
|
1161921-82-9
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY | |||
|
U9DE68P1CA
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY | |||
|
300000004882
Created by
admin on Wed Apr 02 13:52:08 GMT 2025 , Edited by admin on Wed Apr 02 13:52:08 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
